51478 Federal Register / Vol. 73, No. 171 / Wednesday, September 3, 2008 / Notices 

and for pesticides with import 

tolerances only. 

iii. Registration. Like older pesticides, 

all new pesticide registrations must 

meet the safety standard of FFDCA. 

Many of the registration applications 

EPA receives are for new uses of 

pesticides already registered for other 

uses. To reach a decision on a proposed 

new food use of an already registered 

pesticide, EPA must reassess the 

aggregate risk of the the existing 

tolerances, as well as the proposed new 

tolerances, to make sure there is 

reasonable certainty that no harm will 

result to the public from aggregate 

exposure from all uses. 

iv. Tolerance revocations. When EPA 

has canceled use on a particular crop or 

commodity of all products containing a 

pesticide active ingredient, the Agency 

ordinarily will revoke the tolerance, 

unless a party provides data to support 

it as an import tolerance. Some 

pesticides were canceled due to the 

Agency’s risk concerns. Others were 

canceled voluntarily by their 

manufacturers, based on economic 

decisions not to support reregistration. 

Tolerance revocations are important 

even if there are no domestic uses of a 

pesticide because residues in or on 

imported commodities treated with the 

chemical could still present dietary 

risks that may exceed the FFDCA 

‘‘reasonable certainty of no harm’’ 

standard, either individually or 

cumulatively with other substances that 

share a common mechanism of toxicity. 

v. Other reassessment decisions. In 

addition to the types of reassessment 

actions described above, a total of 1,605 

additional tolerance reassessment 

decisions were made. Some were made 

for inert ingredient tolerance 

exemptions through actions not directly 

related to registration or reregistration. 

2. Accomplishments for priority 

pesticides. During FY 2007, EPA 

completed the remaining 84 tolerance 

reassessment decisions for the high 

priority N-methyl carbamate pesticides. 

This completes the reassessment of 

priority pesticides. 

F. Applications for Registration 

Requiring Expedited Processing; 

Numbers Approved and Disapproved 

By law, EPA must expedite its 

processing of certain types of 

applications for pesticide product 

registration, i.e., applications for enduse products that would be identical or 

substantially similar to a currently 

registered product; amendments to 

current product registrations that do not 

require review of scientific data; and 

products for public health pesticide 

uses. During FY 2007, EPA considered 

and approved the numbers of 

applications for registration requiring 

expedited processing (also known as 

‘‘fast track’’ applications) shown in 

Table 6. 

TABLE 6.—FAST TRACK APPLICATIONS

APPROVED IN FY 2007 

Me-too product registrations/Fast 

track 

394 

Amendments/Fast track 3,441 

Total applications processed by 

fast track means 

3,835 

For those applications not approved, 

the Agency generally notifies the 

registrant of any deficiencies in the 

application that need to be corrected or 

addressed before the application can be 

approved. Applications may have been 

withdrawn after discussions with the 

Agency, but none were formally 

‘‘disapproved’’ during FY 2007. 

On a financial accounting basis, EPA 

devoted 25.4 full-time equivalents 

(FTEs) in FY 2007 to reviewing and 

processing applications for fast track 

me-too product registrations and label 

amendments. The Agency spent 

approximately $3.15 million in FY 2007 

in direct costs (i.e., time on task, not 

including administrative expenses, 

computer systems, management 

overhead, and other indirect costs) on 

expedited processing and reviews. 

G. Future Schedule for Reregistrations 

EPA plans to complete the remaining 

27 REDs in FY 2008, meeting the 

October 3, 2008 PRIA deadline. The 

Agency’s schedule for completing these 

decisions is as follows. This schedule 

also is available on EPA’s website at 

http://www.epa.gov/pesticides/ 

reregistration/decision_schedule.htm. 

List 1.—FY 2008 REDs Schedule 

Acrolein 

Busan 77 

Chloropicrin 

Chromated arsenicals (CCA) 

Coal tar/creosote 

Dazomet 

Diiodomethyl p-tolyl sulfone (Amical 

48) 

Ethylene oxide (ETO) (TRED 

completed in FY 2006) 

Formaldehyde 

Grotan 

Inorganic thiosulfates (ammonium 

thiosulfate) 

Methyl bromide (soil fumigant uses; 

commodity uses TRED & RED 

completed FY 2006) 

Methyldithiocarbamate salts (metam 

sodium/metam potassium) 

MITC (methyl isothiocyanate) 

Naphthalene 

Nicotine 

Organic esters of phosphoric acid 

Pentachlorophenol 

Prometon 

Siduron 

Sodium fluoride 

Sulfometuron methyl 

Sumithrin 

Tetramethrin 

Tributyltin-containing compounds 

Triclosan (Irgasan) 

Triforine 

H. Projected Year of Completion of 

Reregistrations 

EPA expects to complete 27 

remaining reregistration eligibility 

decisions in FY 2008. Product 

reregistration, which takes place only 

after the reregistration eligibility 

decisions have been completed for the 

active ingredients, will not likely be 

completed before 2014. 

List of Subjects 

Environmental protection, Pesticides 

and pests. 

Dated: August 22, 2008. 

James B. Gulliford, 

Assistant Administrator, Office of Prevention, 

Pesticides and Toxic Substances. 

[FR Doc. E8–20236 Filed 9–2–08; 8:45 am] 

BILLING CODE 6560–50–S 

FARM CREDIT SYSTEM INSURANCE 

CORPORATION 

Farm Credit System Insurance 

Corporation Board; Regular Meeting 

SUMMARY: Notice is hereby given of the 

regular meeting of the Farm Credit 

System Insurance Corporation Board 

(Board). 

Date and Time: The meeting of the 

Board will be held at the offices of the 

Farm Credit Administration in McLean, 

Virginia, on September 11, 2008, from 

10 a.m. until such time as the Board 

concludes its business. 

FOR FURTHER INFORMATION CONTACT: 

Roland E. Smith, Secretary to the Farm 

Credit System Insurance Corporation 

Board, (703) 883–4009, TTY (703) 883– 

4056. 

ADDRESSES: Farm Credit System 

Insurance Corporation, 1501 Farm 

Credit Drive, McLean, Virginia 22102. 

SUPPLEMENTARY INFORMATION: Parts of 

this meeting of the Board will be open 

to the public (limited space available) 

and parts will be closed to the public. 

In order to increase the accessibility to 

Board meetings, persons requiring 

assistance should make arrangements in 

advance. The matters to be considered 

at the meeting are: 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 73, No. 171 / Wednesday, September 3, 2008 / Notices 51479 

1 The comment must be accompanied by an 

explicit request for confidential treatment, 

including the factual and legal basis for the request, 

and must identify the specific portions of the 

comment to be withheld from the public record. 

The request will be granted or denied by the 

Commission’s General Counsel, consistent with 

applicable law and the public interest. See 

Commission Rule 4.9(c), 16 CFR 4.9(c). 

2 Follow-on biologic drugs refer to those drugs 

that are sufficiently similar to an approved or 

Continued 

Open Session 

A. Approval of Minutes 

• June 12, 2008 

B. Business Reports 

• June 30, 2008 Financial Report 

• Report on Insured and Other 

Obligations 

• Quarterly Report on Annual 

Performance Plan 

C. New Business 

• Annual Performance Plan FY 2009– 

2010 

• Proposed 2009 and 2010 Budgets 

• Insurance Fund Progress Review 

and Setting of Premium Range Guidance 

for 2009 

Closed Session 

• Report on System Performance 

Dated: August 27, 2008. 

Roland E. Smith, 

Secretary, Farm Credit System Insurance 

Corporation Board. 

[FR Doc. E8–20380 Filed 9–2–08; 8:45 am] 

BILLING CODE 6710–01–P 

FEDERAL TRADE COMMISSION 

Public Workshops and Roundtables: 

Emerging Health Care Competition and 

Consumer Issues 

AGENCY: Federal Trade Commission 

ACTION: Notice of Public Workshops and 

Roundtables and Opportunity for 

Comment 

SUMMARY: The Federal Trade 

Commission (‘‘FTC’’ or ‘‘Commission’’) 

announces it will hold two workshops 

and roundtables in the fall of 2008 on 

emerging health care competition and 

consumer issues. They will focus on 

two distinct areas in which competition 

and consumer protection policies are 

implicated: (1) competition provided by 

developing an abbreviated regulatory 

approval pathway for follow-on biologic 

drugs; and (2) competition among health 

care providers based on quality 

information. The workshops and 

roundtables will be held at and 

administered by the FTC and their dates 

will be announced in a separate public 

notice. 

This notice poses a series of questions 

for which the FTC seeks public 

comment. The Commission will 

consider these comments as it prepares 

for the public workshops and 

roundtables. In the spring of 2009, the 

FTC will release a report that analyzes 

the potential impacts on the 

marketplace of various policy options in 

these two areas. 

DATES: Specific dates for the workshops 

and roundtables will be announced 

shortly, along with an agenda. 

Comments on the questions contained 

in this Notice must be received on or 

before September 30, 2008. In addition, 

any interested person may submit 

written comments to any of the topics 

addressed during the workshops. 

Comments directed at a particular 

subject considered in a workshop or 

roundtable must be received no later 

than 30 days after the date of that 

workshop or roundtable. 

ADDRESSES: Interested parties are 

invited to submit written comments 

electronically or in paper form. 

Comments should refer to ‘‘Emerging 

Health Care Competition and Consumer 

Issues—Comment, Project No. P083901’’ 

to facilitate the organization of the 

comments. Comments containing 

material for which confidential 

treatment is requested must be filed in 

paper form, must be clearly labeled 

‘‘Confidential,’’ and must comply with 

Commission Rule 4.9(c).1 Comments 

should not include any sensitive 

personal information, such as an 

individual’s Social Security Number; 

date of birth; driver’s license number or 

other state identification number or 

foreign country equivalent; passport 

number; financial account number; or 

credit or debit card number. Comments 

also should not include any sensitive 

health information, such as medical 

records and other individually 

identifiable health information. 

Because paper mail in the Washington 

area, and specifically to the FTC, is 

subject to delay due to heightened 

security screening, please consider 

submitting your comments in electronic 

form. Comments filed in electronic form 

should be submitted by using the 

following weblink: (http:// 

secure.commentworks.com/ftchealthcarecompetition) and following 

the instructions on the web-based form. 

If this Notice appears at http:// 

www.regulations.gov, you may also file 

an electronic comment through that 

website. The Commission will consider 

all comments that regulations.gov 

forwards to it. 

A comment filed in paper form 

should include the ‘‘Emerging Health 

Care Competition and Consumer 

Issues—Comment, Project No. P083901’’ 

reference both in the text and on the 

envelope, and should be mailed or 

delivered to the following address: 

Federal Trade Commission, Office of the 

Secretary, Room H-135 (Annex F), 600 

Pennsylvania Avenue, NW, Washington, 

DC 20580. 

The Federal Trade Commission Act 

(‘‘FTC Act’’) and other laws the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives, 

whether filed in paper or electronic 

form. Comments received will be 

available to the public on the FTC 

website, to the extent practicable, at 

(http://www.ftc.gov/os/ 

publiccomments.htm.) As a matter of 

discretion, the Commission makes every 

effort to remove home contact 

information for individuals from the 

public comments it receives before 

placing those comments on the FTC 

website. More information, including 

routine uses permitted by the Privacy 

Act, may be found in the FTC’s privacy 

policy, at www.ftc.gov/ftc/ 

privacy.shtmwww.ftc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Michael Wroblewski, Bureau of 

Competition, 600 Pennsylvania Avenue, 

N.W., Washington, D.C. 20580; 

telephone (202) 326-2435; e-mail: 

mwroblewski@ftc.gov. Detailed agendas 

for the workshop will be available on 

the FTC Home Page (http:// 

www.ftc.gov). 

SUPPLEMENTARY INFORMATION: Issues 

arising from the application of 

competition and consumer protection 

law to health care have tremendous 

significance for the U.S. economy and 

consumer/patient welfare. The 2004 

Federal Trade Commission and 

Department of Justice Report, 

‘‘Improving Health Care: A Dose of 

Competition’’ described the economic 

significance of health care to U.S. 

productivity. It has become even more 

so in the intervening four years. The 

Commission has an important role to 

play in health care markets through its 

missions of maintaining competition 

and protecting consumers. 

The Commission intends to focus on 

two emerging areas that implicate both 

its competition and consumer 

protection mission: (1) competition 

provided by developing an abbreviated 

regulatory approval pathway for followon biologic drugs;2 and (2) competition 


sroberts on PROD1PC70 with NOTICES